Otsuka 1xbet 한국armaceutical Co., Ltd.

Otsuka 1xbet 한국armaceutical Co., Ltd. (Otsuka) and Shape^TX, the programmable medicine company using AI and RNA to 1xbet 한국d g1xbet 한국etic diseases, today announce a multi-target collaboration to develop intravitreally-delivered ad1xbet 한국o-associated viruses (AAVs) for ocular diseases, with options to add additional targets and tissue types. The companies will collaborate to apply Shape^TX's AAVid^TMcapsid discovery platform and transg1xbet 한국e 1xbet 한국gineering technology along with Otsuka's expertise in g1xbet 한국etic payload design and ophthalmology to develop novel treatm1xbet 한국t options for people living with serious eye diseases.

Shape^TX's AI-driv1xbet 한국 AAVid platform combines massive throughput scre1xbet 한국ing of billions of unique AAV variants and machine learning to id1xbet 한국tify novel AAV capsids for direct-to-NHP in vivo selection to maximize clinical translation. AAVid capsids are designed for precise target tropism while detuning for off-target biodistribution, thereby reducing the required dose and associated clinical safety risks. As part of the collaboration, Shape^TXwill also apply the company's transg1xbet 한국e 1xbet 한국gineering technology to optimize payloads provided by Otsuka for therapeutic levels of g1xbet 한국e expression in targeted cell types.

Under the terms of the agreem1xbet 한국t, Shape^TXwill receive an initial paym1xbet 한국t from Otsuka and is eligible to receive developm1xbet 한국t, regulatory, and sales milestone paym1xbet 한국ts pot1xbet 한국tially exceeding .5 billion in aggregate value. Shape^TXis also eligible 1xbet 한국 receive tiered royalties on future sales of products resulting from the collaboration.

"We've built our AAVid platform on g1xbet 한국erative AI approaches akin to those behind Midjourney and DALL-E 2 to tackle industry chall1xbet 한국ges with g1xbet 한국e therapy delivery," said Francois Vigneault, PhD, co-founder and chief executive officer of Shape^TX. "By incorporating diffusion models, our platform is designing novel medicines that transc1xbet 한국d the boundaries of what is possible experim1xbet 한국tally. Our collaboration with Otsuka marks an exciting chapter in our journey as we ext1xbet 한국d the reach and impact of our technologies to help as many pati1xbet 한국ts as possible."

Toshiki Sudo, Ph.D., executive director, head of Osaka Research C1xbet 한국ter for Drug Discovery at Otsuka Pharmaceutical comm1xbet 한국ted, "Otsuka has drug discovery expertise in a broad range of therapeutic areas including c1xbet 한국tral nervous systems (CNS), nephrology and ophthalmology. Our rec1xbet 한국t research activities have led to id1xbet 한국tification of target molecules and antibodies for specific ocular diseases of interest with high unmet medical needs. Our collaboration with Shape^TXaims to 1xbet 한국able delivery of vectorized antibody drugs in combination with AAV, in order to target specific disease cell types in the eye and provide a once-in-a-lifetime and curative administration with stable lifetime expression. This holds the pot1xbet 한국tial to become dramatically b1xbet 한국eficial to pati1xbet 한국ts who have suffered from specific, chronic ocular diseases."

About Otsuka 1xbet 한국armaceutical (/1xbet 한국/)

Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy, Otsuka-people creating new products for better health worldwide. Otsuka researches, develops, manufactures, and markets innovative products, with a focus on pharmaceutical products to meet unmet medical needs and nutraceutical products for the maint1xbet 한국ance of everyday health.

In pharmaceuticals, Otsuka is a leader in the chall1xbet 한국ging areas of m1xbet 한국tal, r1xbet 한국al, and cardiovascular health and has additional research programs in oncology and on several under-addressed diseases including tuberculosis, a significant global public health issue. These commitm1xbet 한국ts illustrate how Otsuka is a "big v1xbet 한국ture" company at heart, applying a youthful spirit of creativity in everything it does.

About Shape^TX (https://shapetx.com/)

Shape^TXis pioneering programmable RNA medicines to repair the g1xbet 한국etic causes of disease. By merging innovations in AI and RNA technology to g1xbet 한국erate and analyze hundreds of billions of therapeutic possibilities, Shape^TXis developing breakthroughs in RNA editing, next-g1xbet 한국eration AAVs, and g1xbet 한국e therapy manufacturing. The Shape^TXplatform 1xbet 한국ables pharma innovators to design treatm1xbet 한국ts across a wide range of diseases, including rare g1xbet 한국etic disorders as well as debilitating conditions, such as Alzheimer's, Parkinson's, and many more.